New scan could reveal cancer drug success in days, not months

NCT ID NCT04020978

Completed Diagnosis Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a special PET scan method to see if it could detect early signs that targeted therapy is working for genitourinary cancer. Eleven patients had scans before and two weeks after starting treatment. The goal was to see if changes in tumor blood flow could predict later tumor shrinkage, potentially avoiding months of ineffective and costly treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Parametric PET/CT scan
What this could lead to: If successful, this could lead to a faster way to tell if a cancer treatment is working, saving patients from months of ineffective therapy.
What could go wrong: This is a very small pilot study with only 11 participants, so results may not apply broadly. The method is still experimental and needs much more testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENITOURINARY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant urinary system neoplasm renal cell carcinoma Urogenital Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENITOURINARY CANCER

Contacts and locations

Locations

UC Davis Medical Center

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.